In this issue we have included two recent studies on developmental outcomes in infants that we think will be of interest to many of you.
Purpose of this study This study aimed to assess whether prenatal diagnosis of TSC and early intervention are correlated with better developmental and epilepsy-related outcomes than postnatal diagnosis. About this study This was a retrospective, single-centre study of children with … Read More
Context Previous studies have estimated the incidence of Autism Spectrum Disorder (ASD) to be 17%-61% in children with TSC, and the incidence of epilepsy to be 70%-90%. Several studies suggest 60%-80% of people with TSC experience their first seizure within … Read More
About this study Treatment with mTOR pathway inhibitors is important in drug resistant epilepsy (DRE). This study sought to evaluate the safety and efficacy of 12 months of Rapamycin treatment in 32 paediatric patients aged from 11 months to 14 … Read More
About this study The TuberOus SClerosis registry to increase disease Awareness (TOSCA) Post-Authorization Safety Study (PASS) was a non-interventional, multicenter, safety study that assessed the long-term safety of everolimus in patients with TSC in the European Union. The secondary aims … Read More
Many children are affected by drug-resistant epilepsy (DRE). Drug-resistant epilepsy can cause increased mortality, cognitive impairment/developmental delays and poorer quality of life. It is therefore important to control seizures to reduce developmental delays in paediatric epilepsy. Seizure control may be … Read More
Approximately 75% – 90% of individuals with TSC will have epilepsy at some point in their lives. There is renewed interest in the therapeutic benefits of cannabis medications, especially for individuals affected by treatment-resistant epilepsy, however clear prescribing guidelines for … Read More